Menu Menu

News

Topics
Featured
COVID-19 Research Pipeline

184,435

Registered/ Published

4,522

Registered

838

Published

6,975

Registered
As at 18 November 2022
FILTERED BY > Casirivimab plus imdevimab (Ronapreve) Clear filter

Taskforce notes concerns about potential Ronapreve effectiveness and Omicron

23 December, 2021
The Taskforce has added the following statement to the remark in all for use casirivimab plus imdevimab recommendations. The Taskforce is aware of concerns about the potential for decreased effectiveness of casirivimab plus imdevimab against the Omicron variant, based on in vitro data. We will update this recommendation as definitive evidence becomes available. Ends.
News

Communique #54

26 November, 2021
Click for the latest Taskforce news:
Communique

Communique #52

29 October, 2021
Click for the latest Taskforce news:
Communique

Communique #51

15 October, 2021
WEEK IN REVIEW Updates to the Living Treatment Guidelines New recommendations New recommendation for Continuous positive airway pressure / High-flow nasal oxygen therapy The Hospital and Acute Care...
Communique

Communique #50

29 September, 2021
WEEK IN REVIEW Updates to the Living Treatment Guideline New recommendations Seven new treatment recommendations for pregnant and breastfeeding women Sotrovimab for pregnant women Following recent recommendations for the...
Communique

Communique #47

1 July, 2021
WEEK IN REVIEW Updates to the Living Treatment Guideline New recommendations Three new recommendations for the use of Casirivimab plus imdevimab (REGEN-COV) The Disease-Modifying Treatment and Chemoprophylaxis Panel...
Communique

Guidelines update, v40.2

17 June, 2021
Version 40.2 of the Australian guidelines for the clinical care of people with COVID-19 includes the identification of three new studies on disease-modifying treatments. In addition, the treatment...
News

Guidelines update, v39.1

28 May, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week includes the following change to the evidence summary section for:   REGN-COV2 The...
News

Communique #37

29 January, 2021
Following a well-earned break, the Taskforce team has now returned to full capacity. Global evidence surveillance continued throughout January, with six clinical panel meetings held since January 11....
Communique